Jitka Patockova

A phase 3, open-label, multicenter study of a 6-month pre-mixed depot formulation of leuprolide mesylate in advanced prostate cancer patients

N. Shore, Mark S. DeGuenther, Shih-Tsung Huang, 2019, World Journal of Urology.